Strikingly, MLL–Menin inhibitors also seem to show broad activity against diverse HOX-activating AML oncogenes, suggesting that both these proteins are involved in an epigenetic network that is broadly essential for sustaining HOX gene expression (61). Here, KMT2A is linked to acute myeloid leukemia.